« Back to Record
Citation APA

Kudo, M., Finn, R. R., Edeline, J., Cattan, S., Ogasawara, S., Palmer, D. D., Verslype, C., Zagonel, V., Fartoux, L., Vogel, A., Sarker, D., Verset, G., Chan, S. L., Knox, J., Daniele, B., Yau, T., Gurary, E. E., Siegel, A. A., Wang, A., Cheng, A. L., & Zhu, A. X. (2022). Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib. European journal of cancer, 167, 1-12. doi:10.1016/j.ejca.2022.02.009


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/342427

Kudo, M., Finn, R. R., Edeline, J., Cattan, S., Ogasawara, S., Palmer, D. D., Verslype, C., Zagonel, V., Fartoux, L., Vogel, A., Sarker, D., Verset, G., Chan, S. L., Knox, J., Daniele, B., Yau, T., Gurary, E. E., Siegel, A. A., Wang, A., Cheng, A. L., & Zhu, A. X. (2022). Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib. European journal of cancer, 167, 1-12. doi:10.1016/j.ejca.2022.02.009